Breaking News

WuXi PharmaTech’s Shanghai Facilities Pass FDA Audit

April 30, 2014

Analytical and stability testing, and CTM services deemed compliant

WuXi PharmaTech’s analytical and stability testing facilities in Shanghai Waigaoqiao Free Trade Zone, have passed a GMP inspection by the FDA. The inspection also included clinical trial materials manufacturing for drug products (CTM), packaging and labeling facilities, which were deemed compliant.
"This favorable FDA inspection outcome, in addition to last year's MPA (EMA) approval, reflects the quality of our analytical and stability testing and CTM facilities, the robustness of our quality assurance system, and the high caliber of our employees," said Dr. Ge Li, Chairman and chief executive officer of WuXi PharmaTech. "We are committed to building operations with the highest standards of quality across our entire platform of R&D services."

Related Contract Manufacturing:

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks